ClinicalTrials.gg

Program

fosnetupitant

Also written as “Fosnetupitant 235 mg solution” and “fosnetupitant/ palonosetron”.

Its studies are mostly in Vomiting, led by Helsinn Healthcare.

Furthest: phase 3, since Jan 4, 20182 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Helsinn Healthcare20 open or runningphase 3since Jan 4, 2018Jan 4, 2018none ahead

Also a collaborator on its studies: george-clinical-pty-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 4, 2018First study: phase 3 study in VomitingFirst studyNCT03403712 · 404 enrolled · United States, Georgia
  2. Feb 11, 2025Phase 1 study in Healthy VolunteersNCT06840769 · 50 enrolled · Switzerland

TargetBeta

TACR1 →read by rule
“A prodrug of netupitant, a selective neurokinin 1 receptor (NK1R; TACR1) antagonist, ”NCIt, by rule
“Neurokinin 1 receptor antagonist”ChEMBL 37, by rule

Other programs on TACR1

ProgramCompanyFurthest phaseStudies
AprepitantruleMerckphase 427
elinzanetantruleBayerphase 324
tradipitantruleVanda Pharmaceuticalsphase 319
HRS5580Jiangsu HengRui Medicinephase 22

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06840769Healthy Volunteers · Switzerland1TerminatedOct 18, 202350
NCT03403712Vomiting · United States, Georgia3CompletedSep 19, 2018404

How it is read

Names in the registry

  • “Fosnetupitant 235 mg solution”, 1 entry
  • “fosnetupitant/ palonosetron”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.